Q&A: What is a fractional Chief Medical Officer and when does a biotech need one?
For many biotech companies, the need for senior medical leadership arrives before the business is ready to appoint a full-time Chief Medical Officer. A fractional Chief Medical Officer, or fractional CMO, can provide that expertise on a flexible basis, helping teams make critical clinical, regulatory and strategic decisions without committing to a permanent executive hire too early.
Fractional CMOs are becoming an increasingly valuable option for cost-conscious biotech businesses, particularly those moving from pre-clinical research into clinical development, preparing for investor or regulatory interactions, or bridging a leadership gap while recruiting a permanent CMO.
In this Q&A, Dr Laurence Skillern, Chief Medical Officer at Boyds, explores what fractional CMO support involves and when it can add the most value.
Q: What is a fractional Chief Medical Officer?
A: A fractional Chief Medical Officer is a senior medical leader who works with a company on a part-time, interim or consultancy basis. Rather than joining the business as a permanent full-time executive, a fractional CMO provides strategic and practical medical leadership according to the company’s stage, priorities and budget.
For biotech companies, this model can be especially useful when clinical expertise is needed at a critical inflection point, but a full-time CMO appointment is not yet required. A fractional CMO may support an organization while it searches for a permanent CMO, provide part-time leadership during early development, or bring specialist expertise that is not available within the existing team.
Q: What are the responsibilities of a fractional CMO?
A: The role of a CMO is complex and multifaceted. A fractional CMO may be responsible for shaping clinical strategy, overseeing clinical development plans, supporting regulatory interactions, advising on trial design, interpreting clinical data, representing the company with key stakeholders and ensuring that the patient perspective remains central to decision-making.
In practice, this can include developing the clinical roadmap, advising on target product profiles, supporting patient population selection, preparing for scientific advice meetings or Investigational New Drug (IND) applications, and helping teams interpret clinical, regulatory and pharmaceutical development requirements.
Fractional CMOs also provide internal leadership. They can mentor team members, guide difficult decision-making, support budgetary oversight and help establish appropriate governance, processes and key performance indicators for clinical development.
Q: What are the benefits of a fractional CMO for biotech companies?
A: A fractional CMO gives biotech companies access to experienced medical leadership without the fixed cost of a full-time executive. This can reduce cash expenditures, avoid unnecessary equity commitments and allow organizations to scale medical leadership up or down as the program evolves.
The benefits extend beyond cost. A fractional CMO can provide strategic direction, strengthen clinical trial planning, support regulatory readiness, improve operational discipline and bring credibility to conversations with investors, boards, regulators and potential partners.
Because fractional CMOs often have experience across multiple companies and development programs, they can bring a fresh, objective perspective. This can help biotechs avoid common pitfalls, refine their clinical development strategy and identify opportunities for time and cost savings.
Q: When should a biotech hire a fractional CMO?
A: A biotech should consider hiring a fractional CMO when it needs senior medical judgment but does not yet require, or cannot justify, a permanent full-time CMO. This is often the case for early-stage biotechs, companies preparing to move from preclinical to clinical development, or organizations planning their first clinical trials.
Fractional support may also be valuable during a leadership transition, while recruiting a permanent CMO, or when the company requires specific clinical, regulatory or pharmaceutical development expertise that is not available internally.
Timing is important — bringing in senior medical expertise early can help shape the right regulatory strategy, clinical trial roadmap and evidence-generation plan before costly decisions are made.
Q: How can a fractional CMO support clinical development?
A: A fractional CMO can support clinical development by helping to design and execute programs that are scientifically robust, operationally practical and aligned with the target product profile and regulatory expectations. This may include advising on indication selection, endpoint strategy, trial design, patient care, safety oversight and medical monitoring.
They can also support regulatory affairs teams by preparing for interactions with authorities, strengthening briefing materials and advising on submissions such as IND applications. Their experience can help maximize the value of regulatory meetings and reduce the risk of delays or misalignment.
Where specialist therapeutic area knowledge is required, a fractional CMO can help identify and engage key opinion leaders or establish a scientific advisory board. This can be particularly important when refining patient populations, validating the target product profile or developing a clear clinical trial roadmap.
Q: How does a fractional CMO build trust with investors and stakeholders?
A: For investors, boards and partners, experienced medical leadership provides reassurance that a development program is being guided by informed, objective and accountable decision-making. A fractional CMO can represent the company in external discussions, explain clinical strategy clearly and demonstrate that patient safety, regulatory expectations and commercial objectives are being considered together.
This credibility can be especially important for small or emerging biotechs seeking investment, preparing for regulatory milestones or working to establish confidence in their development plans.
Accelerate your drug development journey with fractional CMO support
Fractional CMOs can help drug developers navigate complex medical, clinical and regulatory challenges without the financial commitment of a full-time executive appointment. Boyds’ team of experienced Pharmaceutical Physicians provides flexible fractional Chief Medical Officer support tailored to your stage of development, whether you are preparing for clinical trials, bridging a leadership gap or waiting to appoint a permanent CMO.
Speak to Boyds to find out how fractional CMO support can strengthen your clinical development strategy and help accelerate your journey from clinic to market.